Building A Biopharma Product's Reimbursement Into Deals
Executive Summary
The growing influence of payors means biopharma companies are grappling with how to incorporate the impact of reimbursement on a product’s market opportunity when structuring deals, executives said at the BIO-Windhover Pharmaceutical Strategic Outlook conference in New York City in February 2010.
You may also be interested in...
CER, Reimbursement Issues Drawing More Attention From Reg Professionals
Pharmaceutical manufacturers’ efforts to address comparative effectiveness and reimbursement issues earlier in their regulatory strategies are borne out in a study showing growing involvement by regulatory professionals in these areas.
Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.
Reimbursement: The New Biopharma Investment Hurdle
With a growing number of expensive therapeutics entering the market and rising pressures to contain costs, gauging reimbursement is now a crucial element deal makers must evaluate.